National Marrow Donor Program, Minneapolis, Minnesota 55413-1753, USA.
Biol Blood Marrow Transplant. 2012 Mar;18(3):348-71. doi: 10.1016/j.bbmt.2011.12.519. Epub 2011 Dec 13.
Advances in hematopoietic cell transplantation (HCT) technology and supportive care techniques have led to improvements in long-term survival after HCT. Emerging indications for transplantation, introduction of newer graft sources (eg, umbilical cord blood) and transplantation of older patients using less intense conditioning regimens have also contributed to an increase in the number of HCT survivors. These survivors are at risk for developing late complications secondary to pre-, peri-, and posttransplantation exposures and risk factors. Guidelines for screening and preventive practices for HCT survivors were published in 2006. An international group of transplantation experts was convened in 2011 to review contemporary literature and update the recommendations while considering the changing practice of transplantation and international applicability of these guidelines. This review provides the updated recommendations for screening and preventive practices for pediatric and adult survivors of autologous and allogeneic HCT.
造血细胞移植(HCT)技术和支持性护理技术的进步导致 HCT 后长期生存得到改善。移植的新适应证、新供体来源(如脐带血)的引入以及使用强度较低的预处理方案对老年患者进行移植,也导致 HCT 幸存者人数增加。这些幸存者由于移植前、移植中和移植后的暴露和危险因素而有发生晚期并发症的风险。2006 年发布了 HCT 幸存者筛查和预防实践指南。2011 年,国际移植专家小组召集会议,审查了当代文献,并在考虑到移植实践的变化和这些指南的国际适用性的情况下更新了建议。本综述提供了用于筛查和预防自体和异基因 HCT 后儿科和成人幸存者的更新建议。